Bulletin
Investor Alert

Seres Therapeutics Inc.

NAS: MCRB

GO
/marketstate/country/us

After Hours

/zigman2/quotes/203151527/composite

$

5.75

Change

-0.14 -2.38%

Volume

Volume 70,394

Sep 23, 2022, 5:16 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/203151527/composite

Previous close

$ 6.03

$ 5.89

Change

-0.14 -2.32%

Day low

Day high

$5.73

$6.01

Open
Open: 5.99

52 week low

52 week high

$2.50

$11.69

Open

Market cap

$730.78M

Average volume

1.12M

P/E ratio

N/A

Rev. per Employee

$410,375

EPS

-1.14

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/mcrb

MarketWatch News on MCRB

  1. Seres inks deal for C. diff drug with Nestlé

    1:45 p.m. July 2, 2021

    - Jaimy Lee

  2. Why ARK Innovation Is a Different Fund Today Than It Was a Year Ago

    7:24 a.m. March 29, 2021

    - Barron's Online

  3. Want to Use ETFs to Play Biotech? Choose Wisely.

    10:30 p.m. Jan. 15, 2021

    - Barron's Online

  4. ARK ETFs Are More Popular Than Ever

    8:37 a.m. Dec. 28, 2020

    - Barron's Online

  5. Owens Corning Scrutinized

    9:30 p.m. July 5, 2019

    - Barron's Online

  6. Seres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapy

    8:58 a.m. Dec. 4, 2017

    - Emma Court

  7. Seres Therapeutics started at outperform with $19 stock price target at Oppenheimer

    7:55 a.m. Oct. 13, 2017

    - Tomi Kilgore

  8. Seres Therapeutics stock drops 10% on early-stage clinical trial results

    9:36 a.m. Oct. 2, 2017

    - Emma Court

  9. Nutanix’s eye-popping post-IPO pop is largest of the year

    4:30 p.m. Sept. 30, 2016

    - Caitlin Huston

  10. Seres Therapeutics downgraded to neutral from buy at BofA Merrill Lynch

    11:10 a.m. Aug. 1, 2016

    - Tomi Kilgore

  11. Seres Therapeutics stock price target cut to $13 from $44 at BofA Merrill Lynch

    11:11 a.m. Aug. 1, 2016

    - Tomi Kilgore

  12. Charting the Market

    2:23 a.m. July 30, 2016

    - Barron's Online

  13. Seres Therapeutics stock plummets 78% after negative midstage trial results

    8:16 a.m. July 29, 2016

    - Emma Court

  14. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/mcrb

Other News on MCRB

  1. Seres Therapeutics: What The Market Is Missing

    7:00 a.m. Aug. 19, 2022

    - Seeking Alpha

  2. 10-Q: SERES THERAPEUTICS, INC.

    10:03 a.m. Aug. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. Notable earnings before Wednesday's open

    10:48 a.m. Aug. 2, 2022

    - Seeking Alpha

  4. Seres Therapeutics: The Good And The Challenging

    1:42 p.m. July 12, 2022

    - Seeking Alpha

  5. Seres Therapeutics stock slips on $100M stock offering

    7:36 a.m. June 30, 2022

    - Seeking Alpha

  6. Seres Therapeutics: The Pipeline Is The Problem

    11:41 a.m. June 10, 2022

    - Seeking Alpha

  7. 10-Q: SERES THERAPEUTICS, INC.

    10:04 a.m. May 4, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  8. Notable earnings before Wednesday's open

    11:43 a.m. May 3, 2022

    - Seeking Alpha

  9. Seres Therapeutics Q1 2022 Earnings Preview

    11:03 a.m. May 3, 2022

    - Seeking Alpha

  10. Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

    10:48 a.m. March 22, 2022

    - Seeking Alpha

  11. Seres Therapeutics Is Playing A Long Game

    8:00 a.m. March 6, 2022

    - Seeking Alpha

  12. Loading more headlines...
/news/pressrelease/company/us/mcrb

Press Releases on MCRB

  1. What to Know About Buying Penny Stocks on June 8th

    7:00 a.m. June 8, 2022

    - Penny Stocks

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.